<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1670">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04434118</url>
  </required_header>
  <id_info>
    <org_study_id>IRB: RC-5-2020</org_study_id>
    <nct_id>NCT04434118</nct_id>
  </id_info>
  <brief_title>Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients</brief_title>
  <official_title>Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients: A Retrospective, Case-control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sadat City University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sadat City University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid arthritis (RA) patients have an underlying immune deficiency and typically treated
      with immunosuppressive drugs, which may increase the risk of COVID-19 infection.
      Hydroxychloroquine (HCQ) has been found to possess antiviral activity against COVID-19. Thus,
      the aim of this study to investigate the ability of HCQ to reduce the risk of COVID-19 among
      RA patients.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 20, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The risk of COVID-19 infection among RA patients</measure>
    <time_frame>12 week</time_frame>
    <description>Realtion between hydroxychloroquine use and COVID-19 infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of hospitalization for Covid-19 patients.</measure>
    <time_frame>12 week</time_frame>
    <description>Number of cases and number of hospitalization days</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">600</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>Rheumatoid Arthritis with COVID-19</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Rheumatoid Arthritis without COVID-19</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Traditional antirheumatic drugs</intervention_name>
    <description>Hydroxychloroqine, Methotrexate, Glucocorticoids, Leflunomide, and Sulphasalazine</description>
    <arm_group_label>Rheumatoid Arthritis with COVID-19</arm_group_label>
    <arm_group_label>Rheumatoid Arthritis without COVID-19</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients fulfilling 2010 ACR-EULAR classification criteria for RA
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Data of all definite cases of RA were collected and reviewed from complete medical
        records of patients by a team that included 2 trained physicians using a pretested data
        collection form.

        Exclusion Criteria:

          -  The exclusion criteria were included incomplete medical records or those with
             difficulty to communicate with the patients.

          -  Patients with acute lethal organ injury (e.g., acute myocardial infarction, acute
             coronary syndrome, acute pulmonary embolism, or acute stroke)

          -  Patients with decompensated or end stage chronic organ dysfunction (e.g.,
             decompensated cirrhosis, decompensated chronic renal insufficiency, or severe
             congestive heart failure), diabetes mellitus, data of pregnant females, acquired
             immune deficiency syndrome (aids), and leukemia or other malignancies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>ShibÄ«n Al Kawm</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 13, 2020</study_first_submitted>
  <study_first_submitted_qc>June 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>October 4, 2020</last_update_submitted>
  <last_update_submitted_qc>October 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sadat City University</investigator_affiliation>
    <investigator_full_name>Mahmoud Samy Abdallah</investigator_full_name>
    <investigator_title>Lecturer of Clinical Pharmacy, PhD.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

